John Zajecka, MD

Safety and Tolerability of Concomitant Intranasal Esketamine and MAOI Treatment

February 1, 2023

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in some patients.

Margarete A. Wallner, Joshua C. Eloge, Ian V. Mackey, et al

Academic Highlights

Residual Symptoms in Major Depressive Disorder: Prevalence, Effects, and Management

April 27, 2013

John Zajecka, Susan G. Kornstein, Pierre Blier

Academic Highlights

Residual Symptoms in Major Depressive Disorder: Prevalence, Effects, and Management

April 15, 2013

John Zajecka, Susan G. Kornstein, Pierre Blier

Original Research

Sexual Function and Satisfaction in the Treatment of Chronic Major Depression With Nefazodone, Psychotherapy, and Their Combination

August 15, 2002

John Zajecka, David L. Dunner, Alan J. Gelenberg, et al

Original Research

Symptomatic and Syndromal Anxiety in Chronic Forms of Major Depression: Effect of Nefazodone, Cognitive Behavioral Analysis System of Psychotherapy, and Their Combination

May 12, 2002

Philip T. Ninan, A. John Rush, Paul Crits-Christoph, et al

Article

Antidepressant Dosing and Switching Guidelines: Focus on Nefazodone

January 1, 2002

John Zajecka, Geoffry W. McEnany, Kimberly M. Lusk

Article

Six-Year Perspectives on the Safety and Tolerability of Nefazodone

January 1, 2002

David L. Dunner, Lyle K. Laird, John Zajecka, et al

Original Research

Efficacy and Safety of Mirtazapine in Major Depressive Disorder Patients After SSRI Treatment Failure: An Open-Label Trial

June 1, 2001

Maurizio Fava, David L. Dunner, John H. Greist, et al

Article

Strategies for the Treatment of Antidepressant-Related Sexual Dysfunction

February 1, 2001

John Zajecka

Article

Strategies for the Treatment of Antidepressant-Related Sexual Dysfunction

February 1, 2001

John Zajecka

Original Research

Changes in Adverse Events Reported by Patients During 6 Months of Fluoxetine Therapy

June 30, 1999

John Zajecka, Jay D. Amsterdam, Frederic M. Quitkin, et al

Article

Clinical Management of Antidepressant Discontinuation

August 1, 1997

Jerrold F. Rosenbaum, John Zajecka

Safety and Tolerability of Concomitant Intranasal Esketamine and MAOI Treatment

Residual Symptoms in Major Depressive Disorder: Prevalence, Effects, and Management

Residual Symptoms in Major Depressive Disorder: Prevalence, Effects, and Management

Sexual Function and Satisfaction in the Treatment of Chronic Major Depression With Nefazodone, Psychotherapy, and Their Combination

Symptomatic and Syndromal Anxiety in Chronic Forms of Major Depression: Effect of Nefazodone, Cognitive Behavioral Analysis System of Psychotherapy, and Their Combination

Antidepressant Dosing and Switching Guidelines: Focus on Nefazodone

Six-Year Perspectives on the Safety and Tolerability of Nefazodone

Efficacy and Safety of Mirtazapine in Major Depressive Disorder Patients After SSRI Treatment Failure: An Open-Label Trial

Strategies for the Treatment of Antidepressant-Related Sexual Dysfunction

Strategies for the Treatment of Antidepressant-Related Sexual Dysfunction

Changes in Adverse Events Reported by Patients During 6 Months of Fluoxetine Therapy

Clinical Management of Antidepressant Discontinuation

ELSEWHERE:

FOLLOW US:

John Zajecka, MD

Safety and Tolerability of Concomitant Intranasal Esketamine and MAOI Treatment

Residual Symptoms in Major Depressive Disorder: Prevalence, Effects, and Management

Residual Symptoms in Major Depressive Disorder: Prevalence, Effects, and Management

Sexual Function and Satisfaction in the Treatment of Chronic Major Depression With Nefazodone, Psychotherapy, and Their Combination

Symptomatic and Syndromal Anxiety in Chronic Forms of Major Depression: Effect of Nefazodone, Cognitive Behavioral Analysis System of Psychotherapy, and Their Combination

Antidepressant Dosing and Switching Guidelines: Focus on Nefazodone

Six-Year Perspectives on the Safety and Tolerability of Nefazodone

Efficacy and Safety of Mirtazapine in Major Depressive Disorder Patients After SSRI Treatment Failure: An Open-Label Trial

Strategies for the Treatment of Antidepressant-Related Sexual Dysfunction

Strategies for the Treatment of Antidepressant-Related Sexual Dysfunction

Changes in Adverse Events Reported by Patients During 6 Months of Fluoxetine Therapy

Clinical Management of Antidepressant Discontinuation

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles